For the Inventor, By the Inventor

Enter assignee name

La Jolla, CA, United States of America

Ambrx, Inc.

USPTO Granted Patents = 117

% Expired Patents = 29.1

CIPO Patents = 15

EPO Patents = 42

Trademarks = 2

Forward Citations = 1,519

Loading Chart...

Loading Chart...

89 inventors (with patents filed for the assignee):

Nick Knudsen (36 out of 37 patents)

Feng Tian (31 out of 37 patents)

Vadim Kraynov (29 out of 32 patents)

4. Thea Norman (29 out of 39 patents)

5. Zhenwei Miao (28 out of 50 patents)

6. Jason Pinkstaff (28 out of 28 patents)

7. Ho Sung Cho (28 out of 29 patents)

8. Anna-Maria A Hays Putnam (26 out of 26 patents)

9. Junjie Liu (20 out of 38 patents)

10. Troy Edward Wilson (17 out of 55 patents)

11. Anna-Maria A Hays (15 out of 15 patents)

12. Russell Driver (14 out of 15 patents)

13. Lillian Skidmore (13 out of 13 patents)

14. Thomas O Daniel (13 out of 15 patents)

15. Stephanie Chu (12 out of 12 patents)

Core Competencies:

Antibody Drug Conjugates

Modified Polypeptides

Non-Natural Amino Acids

Protein Production

Therapeutic Uses

Human Growth Hormone

Relaxin Polypeptides

FGF-21 Variants

Bioconjugates

Transcription Methods

Erythropoietin Polypeptides

Suppressor tRNA

117 patents: Sort by Forward Citations

1. 12653897 - PEGYLATED PORCINE INTERFERON AND METHODS OF USE THEREOF (2026-06-16),

2. 12622944 - Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives (2026-05-12),

3. 12577575 - METHODS AND COMPOSITIONS FOR PROMOTING NON-NATURAL AMINO ACID-CONTAINING PROTEIN PRODUCTION (2026-03-17),

4. 12569566 - COMPOSITIONS CONTAINING, METHODS AND USES OF ANTIBODY-TLR AGONIST CONJUGATES (2026-03-10),

5. 12404512 - Method for optimizing antibody expression (2025-09-02),

6. 12377294 - Anti-CD3 antibody folate bioconjugates and their uses (2025-08-05),

7. 12286462 - Porcine G-CSF variants and their uses (2025-04-29),

8. 12059473 - Humanized anti-prostate -specific membrane antigen (PSMA) antibody drug conjugates (2024-08-13),

9. 12049485 - Interleukin-2 polypeptide conjugates and their uses (2024-07-30),

10. 12037405 - Anti-CD70 antibody drug conjugates (2024-07-16),

11. 11993637 - Modified FGF-21 polypeptides with non-naturally encoded amino acids (2024-05-28),

12. 11851662 - Methods and compositions for promoting non-natural amino acid-containing protein production (2023-12-26),

13. 11851488 - Anti-CD3-folate conjugates and their uses (2023-12-26),

14. 11786578 - Modified relaxin polypeptides and their uses (2023-10-17),

15. 11773150 - Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors (2023-10-03),

Company Overview

Ambrx, Inc., based in La Jolla, California, specializes in protein engineering with a focus on developing innovative therapeutic solutions. The company is known for its expertise in antibody drug conjugates and the use of modified polypeptides, including non-natural amino acids, to enhance protein production and therapeutic efficacy. Their research encompasses various applications, including human growth hormone and relaxin polypeptides, as well as FGF-21 variants, positioning Ambrx at the forefront of advanced biopharmaceutical development.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

117 Patents

#5 in La Jolla, CA

#746 in California

#3,292 in US

#6,794 in the World

La Jolla, CA, United States of America

Ambrx, Inc.

Forward Citations = 1,519

89 inventors:

Nick Knudsen (36 out of 37 patents)

Feng Tian (31 out of 37 patents)

Vadim Kraynov (29 out of 32 patents)

4. Thea Norman (29 out of 39 patents)

5. Zhenwei Miao (28 out of 50 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Ambrx, Inc.. Retrieved from https://idiyas.com/company/ambrx

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…